German (DAX) Medical Equipment Industry Analysis

Industry Valuation and Performance

Has the German Medical Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 17 Jun 2026	€48.5b	€33.5b	€2.5b	18.8x	19.2x	1.4x
Fri, 15 May 2026	€47.7b	€33.5b	€2.5b	18.2x	18.9x	1.4x
Sun, 12 Apr 2026	€51.5b	€33.7b	€2.6b	16.4x	20x	1.5x
Tue, 10 Mar 2026	€54.1b	€33.6b	€2.5b	16.4x	21.4x	1.6x
Thu, 05 Feb 2026	€58.2b	€33.7b	€2.6b	16.9x	22.6x	1.7x
Sat, 03 Jan 2026	€60.3b	€33.7b	€2.6b	20.2x	23.5x	1.8x
Mon, 01 Dec 2025	€59.9b	€33.7b	€2.6b	20.1x	23.2x	1.8x
Wed, 29 Oct 2025	€66.5b	€33.6b	€2.6b	21.1x	25.3x	2x
Fri, 26 Sep 2025	€57.8b	€32.0b	€2.6b	17.4x	22.5x	1.8x
Sun, 24 Aug 2025	€61.4b	€32.0b	€2.6b	22.3x	23.9x	1.9x
Tue, 22 Jul 2025	€60.0b	€31.7b	€2.5b	22.8x	23.8x	1.9x
Thu, 19 Jun 2025	€60.0b	€31.7b	€2.5b	21.1x	23.8x	1.9x
Sat, 17 May 2025	€64.4b	€31.7b	€2.5b	30.5x	25.7x	2x
Mon, 14 Apr 2025	€56.9b	€31.2b	€2.4b	25.3x	23.5x	1.8x
Wed, 12 Mar 2025	€66.5b	€31.1b	€2.4b	29.1x	28.1x	2.1x
Fri, 07 Feb 2025	€72.8b	€30.8b	€2.3b	28.4x	31.1x	2.4x
Sun, 05 Jan 2025	€64.5b	€30.8b	€2.3b	25.1x	27.5x	2.1x
Tue, 03 Dec 2024	€66.3b	€30.8b	€2.4b	26.5x	28.1x	2.2x
Thu, 31 Oct 2024	€62.4b	€30.5b	€2.3b	26.2x	27.3x	2x
Sat, 28 Sep 2024	€69.7b	€30.5b	€2.3b	26.2x	30.4x	2.3x
Mon, 26 Aug 2024	€66.2b	€30.5b	€2.3b	26.9x	28.9x	2.2x
Wed, 24 Jul 2024	€67.7b	€30.2b	€2.3b	25.9x	29.8x	2.2x
Fri, 21 Jun 2024	€68.6b	€30.2b	€2.3b	26.1x	30.2x	2.3x
Sun, 19 May 2024	€70.9b	€30.2b	€2.3b	28.6x	31.2x	2.3x
Tue, 16 Apr 2024	€72.0b	€30.2b	€2.0b	25.3x	36.5x	2.4x
Thu, 14 Mar 2024	€76.6b	€30.2b	€2.0b	32.2x	39x	2.5x
Sat, 10 Feb 2024	€73.6b	€30.1b	€2.0b	33.7x	37.6x	2.4x
Mon, 08 Jan 2024	€69.1b	€30.1b	€1.9b	30.4x	35.8x	2.3x
Wed, 06 Dec 2023	€68.9b	€30.0b	€1.9b	28.6x	35.3x	2.3x
Fri, 03 Nov 2023	€63.5b	€30.0b	€2.0b	29.3x	31.1x	2.1x
Sun, 01 Oct 2023	€68.8b	€29.9b	€2.0b	27.2x	34.4x	2.3x
Tue, 29 Aug 2023	€62.3b	€29.9b	€2.0b	29x	31.2x	2.1x
Thu, 27 Jul 2023	€70.6b	€29.7b	€1.8b	31.8x	38.4x	2.4x
Sat, 24 Jun 2023	€69.9b	€29.7b	€1.8b	30.6x	38.1x	2.4x

Current Industry PE

Investors are pessimistic on the German Medical Equipment industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 19.2x which is lower than its 3-year average PE of 28.5x.

The 3-year average PS ratio of 2.1x is higher than the industry's current PS ratio of 1.4x.

Past Earnings Growth

The earnings for companies in the Medical Equipment industry have grown 11% per year over the last three years.
Revenues for these companies have grown 4.1% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the German Healthcare industry?


DE Market	1.53%
Healthcare	-0.45%
Medical Equipment	0.062%
Medical Supplies	1.08%
Medical Equipment	0.043%

Industry PE

Investors are most optimistic about the Medical Supplies industry even though it's trading below its 3-year average PE ratio of 25.4x.

It looks like they are confident that earnings will grow faster in the future than they have historically.

Investors are most pessimistic about the Medical Equipment industry, which is trading below its 3-year average of 28.7x.

Forecasted Growth

Analysts are most optimistic on the Medical Equipment industry, expecting annual earnings growth of 14% over the next 5 years.
However this is lower than its past earnings growth rate of 22% per year.

In contrast, the Medical Equipment industry is expected to see its earnings grow by 14% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
OBCK Ottobock SE KGaA	€51.50	1.6% +€51.2m	n/a	PE35.9x
PHH2 Paul Hartmann	€208.00	1.5% +€10.7m	-16.1%	PE12.1x
SBS Stratec	€18.50	3.9% +€8.5m	-21.1%	PS0.9x
NN6 NanoRepro	€2.00	14.6% +€3.2m	21.2%	PS4.9x
V0R BiBBInstruments	€0.046	1.8% +€128.8k	-81.6%	PS170.6x

Pentixapharm Holding AG Announces Positive Feedback From FDA For Initiation Of Phase III PANDA Study With [68Ga]Ga-PentixaFor

Pentixapharm Holding AG announced the positive feedback from the FDA ('study may proceed') for the initiation of the Phase III PANDA study with [68Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over USD 1,000 million for [68Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine. High blood pressure is one of the most common and consequential widespread diseases worldwide. In the United States alone, Center for Disease Control (CDC) data shows nearly 120 million adults are affected – approximately 48% of the adult population. More than 87 million hypertensive patients are considered treatment-resistant or uncontrolled: they take medication but continue to suffer from hypertension. A frequently overlooked cause driving treatment resistance is Primary Hyperaldosteronism (PA). Studies show that PA is responsible for 5–10% of all hypertensive patients – corresponding to approximately 6,500,000–7,000,000 individuals in the United States. PA and its subtypes remain chronically underdiagnosed today. In particular, adrenal vein sampling (AVS) – the invasive procedure used for treatment-defining diagnostics – is technically demanding and availability is restricted. The result: most PA patients receive lifelong medical treatment, even though a subset could be permanently cured through a single surgical procedure. With [68Ga]Ga-PentixaFor, Pentixapharm offers a non-invasive diagnostic method: using a PET/CT scan, the precise locations in adrenal tissue responsible for excessive aldosterone production can be identified. This enables an accurate and cost-efficient differential diagnosis for determining whether a patient should undergo surgery or receive medical treatment. Several factors also support a rapid and sustainable market penetration for [68Ga]Ga-PentixaFor: AACE, AHA, ESE, ESH, ISH and the Primary Aldosteronism Foundation have actively recommended screening for Primary Hyperaldosteronism in all hypertensive patients since 2025. The radiolabeling of [68Ga]Ga-PentixaFor follows established standards (analogous to e.g. NETSPOT). Equipment and personnel are already available in most US radiopharmacies – no new investment required. [68Ga]Ga-PentixaFor replaces a complex, invasive diagnostic procedure involving high radiation exposure with a PET/CT scan. In addition to greater patient acceptance, positive financial effects for payers are anticipated. In contrast to the PSMA market with approximately 30,000 annually treatable patients, the potential for [68Ga]Ga-PentixaFor amounts to up to 6,500,000–7,000,000 patients in the United States alone. Pentixapharm has received clearance from the US regulatory authority FDA to clinically evaluate PentixaFor in the United States. Starting in the second half of the year, the company will initiate the Phase III PANDA study – a large-scale, multi-center trial enrolling approximately 270 patients – to demonstrate that PentixaFor can replace and expand upon the existing diagnostic procedure. Subject to the study proceeding as planned, the US market launch is scheduled for 2030. [68Ga]Ga-PentixaFor is a gallium-68-labeled radiodiagnostic for the selective visualization of the chemokine receptor CXCR4 by means of high-resolution PET/CT imaging. Clinical experience in more than 2,000 patients across various indications has confirmed its ability to non-invasively image CXCR4 expression in vivo.

German (DAX) Medical Equipment Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Hologic, Inc. Secures Patent Victory Against Siemens over Breast Cancer Detection Technology

Upcoming dividend of €0.60 per share

ZEISS Reports Positive Early Results for AT LUCIA Toric Lens Ahead of 2026 European Launch

Pentixapharm Holding AG Announces Positive Feedback From FDA For Initiation Of Phase III PANDA Study With [68Ga]Ga-PentixaFor

Eckert & Ziegler Expands Lead-212 Therapies With New Partnership and Reports Strong Earnings Growth

High number of new and inexperienced directors

BiBBInstruments AB Presents Clinical Experience With EndoDrill GI At ESGE Days 2026

New minor risk - Financial data availability

aap Implantate AG, Annual General Meeting, Jun 23, 2026

First quarter 2026 earnings released: EPS: €0.30 (vs €0.27 in 1Q 2025)

There May Be Reason For Hope In Paul Hartmann's (FRA:PHH2) Disappointing Earnings

New major risk - Financial data availability